<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T02:44:27Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/24966" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/24966</identifier><datestamp>2026-09-24T00:10:46Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Mishra, Ram</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Tran, Judith</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Neuroscience</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2019-10-07T13:46:05Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2019-10-07T13:46:05Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2019</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/24966</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/8253</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Parkinson’s Disease is a chronic progressive neurodegenerative disease that &#xd;
affects approximately 2000 out of 100 000 people over the age of 80. This disease is &#xd;
typically characterized by impaired motor function, as well as cognitive and autonomic &#xd;
dysfunction as the pathology worsens. The two main hallmarks typically associated with &#xd;
PD are the dopaminergic loss in the nigrostriatal pathway and the presence of Lewy &#xd;
bodies. However, a cellular dysfunction has been commonly found in neurodegenerative &#xd;
diseases, known as the hyperactivation of the Cdk5/p25 complex. This complex is an &#xd;
essential target to focus on the protection of neurons and prevent the pathology of PD to &#xd;
worsen as treatments are currently only temporary in symptom relief. Truncated Peptide 5 &#xd;
(TP5) is a Cdk5/p25 inhibitor that has demonstrated potential therapeutic effects in &#xd;
neurodegenerative disease models such as Alzheimer’s Disease. Paraquat is an herbicide &#xd;
that has implicated Parkinson’s Disease symptoms in those who have been exposed to &#xd;
this toxin. The purpose of this study was to explore TP5’s therapeutic effects to determine &#xd;
if TP5 has the potential drug to treat towards PD. TP5 was tested in vitro and in vivo &#xd;
models that are exposed to paraquat to induce Parkinson’s Disease like phenotypes and &#xd;
biochemical features. A truncated fragment of TP5, known as Peptide A, was also further &#xd;
explored to determine potential therapeutic effects like TP5. TP5 has shown its ability to &#xd;
protect differentiated SH-SY5Y cells and the dopaminergic morphology and behaviour of &#xd;
C. elegans when exposed to paraquat. These results further support that TP5 has &#xd;
neuroprotective effects against models of Parkinson’s Disease. TP5 was also able to &#xd;
regulate the physiological mechanism of Cdk5, such as neurite outgrowth, to further understand its relationship with Cdk5 activity. Lastly, TP5 restored dopaminergic &#xd;
morphology against worms exposed to paraquat. These results suggest TP5 influences the &#xd;
pathology of PD, in both neuroprotective and neurorestorative manner, to confirm that &#xd;
TP5’s potential as a therapeutic drug for Parkinson’s Disease.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Neuroscience</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Parkinson's Disease</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">TP5: A POTENTIAL THERAPEUTIC DRUG FOR PARKINSON’S DISEASE</dim:field>
   <dim:field mdschema="dc" element="title" qualifier="alternative" lang="en_US">INVESTIGATING THE THERAPEUTIC EFFECTS OF TRUNCATED PEPTIDE 5, A CDK5/P25 INHIBITOR, IN AN IN VITRO AND IN VIVO MODEL OF PARKINSON’S DISEASE</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>